Bicuspid aortic valve disease market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6% in the above mentioned forecast period.
Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bicuspid-aortic-valve-disease-market
Bicuspid aortic valve disease (BAV) referred to the most common congenital heart abnormality. The aortic valve is a one-way valve that connects the heart to the aorta, the primary artery that carries oxygen-rich blood from the heart to the rest of the body. The aortic valve normally contains three tiny flaps or leaflets that open widely and close tightly to regulate blood flow, allowing blood to pass from the heart to the aorta while preventing blood from returning to the heart. The valve has only two leaflets in bicuspid aortic valve disease (BAVD). The valve may not work correctly because of this abnormality, yet it may function well for years without creating symptoms or noticeable evidence of a problem.
The rise in the prevalence of bicuspid aortic valve disease is the major driver resulting in the expansion of market’s growth. Another significant factor influencing the growth rate of bicuspid aortic valve disease market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, growing government funding and rising initiatives by public and private organisations to spread awareness are the factors that will expand the bicuspid aortic valve disease market.
North America dominates the bicuspid aortic valve disease market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
Some of the major players operating in the bicuspid aortic valve disease market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin, Pierre Fabre group, ANI Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., AstraZeneca, Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi, Bayer AG, Merck & Co., Inc., AbbVie Inc., UCB S.A., and Bausch Health Companies Inc., among others.
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]
Transcatheter aortic valve replacement (TAVR) or Transcatheter aortic valve implantation (TAVI) is a minimally invasive surgical process that repairs the aortic valve by replacing a new biological valve into the old aortic valve’s place without the need of removing damaged valve.https://brandessenceresearch.com/healthcare/transcatheter-aortic-valve-replacement-market
The source of the artificial valve used, includes mechanical valves, which are created from man-made materials; and tissue valves, which are created from pig, cow, or human donors.
Minimally invasive surgeries include aortic valve balloon valvuloplasty, transcatheter aortic valve implantation (TAVI), and sutureless aortic valve replacement, among others.
Hospitals, ambulatory surgical centers and cardiac catheterization laboratories form the major end-users for the market.
In addition, changing lifestyles, leading to obesity; increasing cardiovascular diseases, growing health awareness, and increasing global geriatric population also contribute to the growth of the aortic valve replacement market.
The risks associated with the replacement procedures, high costs, and growing regulations related to product approvals, would negatively impact the aortic valve replacement market.TAVI, and aortic valve replacement employing a tissue valve, are the common techniques used for aortic valve replacement.
In terms of geography, North America had the largest share in the aortic valve replacement market followed by Europe due to the increasing obesity and growing geriatric population in the region.
